If You Invested in Cencora Inc. (COR)
Looking for the live price? See the COR quote & overviewWhat $1,000 or $10,000 in COR Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jul 13, 2015 |
|---|---|---|---|---|
| $1,000 | $1,017 +2% | $2,169 +117% | $3,680 +268% | $2,748 +175% |
| $10,000 | $10,173 +2% | $21,691 +117% | $36,805 +268% | $27,479 +175% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for COR$1,000 Investment Over Time
COR vs S&P 500Year-by-Year Returns
COR annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2017 | $82.61 | $91.82 | +11.1% | +11.1% |
| 2018 | $94.04 | $74.40 | -20.9% | -9.9% |
| 2019 | $74.45 | $85.02 | +14.2% | +2.9% |
| 2020 | $85.08 | $125.28 | +47.2% | +51.7% |
| 2021 | $121.48 | $132.89 | +9.4% | +60.9% |
| 2022 | $132.62 | $165.71 | +25.0% | +100.6% |
| 2023 | $164.29 | $205.38 | +25.0% | +148.6% |
| 2024 | $208.54 | $224.68 | +7.7% | +172.0% |
| 2025 | $224.74 | $337.75 | +50.3% | +308.8% |
| 2026 | $338.87 | $302.46 | -10.7% | +266.1% |
About Cencora Inc.
Wholesale-drugs, Proprietaries & Druggists' Sundries · NYSE
Cencora, Inc. (NYSE: COR) is a global pharmaceutical solutions organization in the wholesale trade sector, with a core focus on the secure and reliable distribution of pharmaceuticals and healthcare products. The company is described in its public communications as a partner to pharmaceutical innovators across the value chain, helping to facilitate and optimize market access to therapies for both people and animals. Care providers depend on Cencora for delivery of pharmaceuticals, healthcare products, and related solutions that support positive health outcomes.
Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, reflecting its scale as a large U.S.-listed company. The company reports more than $300 billion in annual revenue in recent communications and has stated that it employs over 51,000 team members worldwide. Its purpose, as repeatedly highlighted in its news releases, is that it is "united in its responsibility to create healthier futures."
Business focus and industry role
According to Cencora’s descriptions in earnings releases and press announcements, the company operates a pharmaceutical-centric strategy built around pharmaceutical distribution and complementary healthcare services. It is categorized in the industry group "Drugs and Druggists' Sundries Merchant Wholesalers," and its activities include sourcing and distributing branded, generic, and specialty pharmaceutical products. Polygon data further notes that Cencora is one of three major domestic pharmaceutical wholesalers and that it, together with McKesson and Cardinal Health, accounts for a substantial share of the U.S. pharmaceutical wholesale industry.
Polygon data also indicates that Cencora’s operations extend beyond core drug wholesaling into areas such as commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics through its World Courier business, and animal health product distribution through MWI Animal Health. In 2021, Cencora expanded its international presence by purchasing Alliance Healthcare, described as one of the leading drug wholesalers in Europe.
Segments and solutions
Cencora organizes its activities into reportable segments that reflect its geographic and operational structure. In its fiscal 2025 and 2026-related filings and releases, the company describes two primary reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. U.S. Healthcare Solutions includes U.S. human health operations, such as pharmaceutical distribution and related services to health systems, physician practices, and other care providers. International Healthcare Solutions includes Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex, as outlined in an 8-K describing a revised reporting structure.
Cencora has also disclosed an "Other" category, which is not a reportable segment, that includes businesses for which the company is exploring strategic alternatives. According to an 8-K, this category includes MWI Animal Health, Profarma, U.S. Consulting Services, and other components of PharmaLex.
Specialty care, oncology, and data-driven offerings
Recent company communications emphasize Cencora’s focus on specialty pharmaceuticals and specialty care. The company highlights investments and acquisitions that enhance its position in specialty segments, such as the acquisition of Retina Consultants of America (RCA), which contributed to increased gross profit and operating income in its U.S. Healthcare Solutions segment. Cencora has also announced an agreement to acquire the majority of the outstanding equity interests it does not already own in OneOncology, a physician-led national platform for independent medical specialty practices rooted in oncology, as disclosed in both a press release and a Form 8-K.
Within Cencora, IntrinsiQ Specialty Solutions is described as a leader in data analytic solutions and part of the company’s specialty-focused offerings. IntrinsiQ provides expanded data and insights for oncology, retina, and other therapeutic areas, including oncology biomarker data. According to a Cencora news release, IntrinsiQ’s data and insights help biopharmaceutical manufacturers and physicians understand how therapies are utilized in real-world settings, support precision medicine approaches, and inform education and outreach to clinicians.
Distribution network and infrastructure
Cencora has announced significant planned investments in its distribution infrastructure. In a fiscal 2025 earnings release, the company reported plans for $1 billion in investments through 2030 to strengthen its U.S. distribution network, expand capacity, and increase resilience. These investments include opening a second national distribution center, expanding multiple distribution center facilities, and increasing cold chain storage capacity to support the growth of specialty pharmaceuticals.
The company’s receivables securitization facility, described in a June 2025 Form 8-K, is used to provide liquidity and funding for ongoing business needs. Subsidiaries such as AmerisourceBergen Drug Corporation (ABDC) and ASD Specialty Healthcare, LLC originate accounts receivable from the sale of pharmaceuticals and related products and services, which are then sold into a securitization structure. This facility is based on receivables from the sale of pharmaceuticals and other related products and services and is one of the mechanisms Cencora uses to support its large-scale distribution operations.
Financial scale and capital structure
Cencora’s earnings releases for fiscal 2025 describe revenue in the hundreds of billions of dollars, with growth across both U.S. Healthcare Solutions and International Healthcare Solutions. The company reports on both GAAP and non-GAAP (adjusted) measures, including adjusted operating income and adjusted diluted earnings per share, and provides detailed reconciliations in its financial disclosures.
Several Form 8-K filings describe the company’s financing arrangements, including senior notes and credit facilities. Cencora has 2.875% Senior Notes due 2028 and 3.625% Senior Notes due 2032 listed on the New York Stock Exchange under symbols COR28 and COR32, in addition to its common stock under the symbol COR. The company has also amended a senior unsecured term loan and a money market facility, as disclosed in September 2025 8-K filings, and has obtained bridge financing commitments to support the planned OneOncology acquisition.
Corporate governance and leadership changes
Cencora’s public filings and news releases document changes in its board and governance structure. In August 2025, the company announced that D. Mark Durcan, previously Lead Independent Director, would be appointed Chairman of the Board effective October 1, 2025, succeeding Steven H. Collis, who had served as Chairman and previously as Chief Executive Officer. The same period also saw the election of Lori J. Ryerkerk as a new independent director, bringing experience in complex global supply chains and manufacturing operations.
The company has also reported on the resolution of a stockholder derivative action related to oversight of controlled substance diversion control programs. In a September 2025 Form 8-K, Cencora described a proposed settlement under which insurance carriers would pay the company a specified amount, subject to court approval, with no admission of liability by the defendants.
Purpose, culture, and corporate responsibility
Across its press releases, Cencora consistently emphasizes its purpose-driven culture and focus on health outcomes. The company states that its team members contribute to positive health outcomes through the power of its purpose: being united in the responsibility to create healthier futures. Cencora has also highlighted the release of a Corporate Responsibility Report, describing an emphasis on business resiliency and sustainable operations, with selected information in the report assured by an external certification and verification service.
Cencora’s communications also reference its focus on digital transformation, investment in talent and culture, and productivity as strategic drivers. The company describes itself as a healthcare services provider with a pharmaceutical distribution footprint and complementary end-to-end services and solutions, supporting community providers, specialty physician practices, and other stakeholders across the healthcare ecosystem.
Stock information and exchange listing
Cencora’s common stock trades on the New York Stock Exchange under the ticker symbol COR, as confirmed in multiple Form 8-K filings. The same filings list its senior notes under COR28 and COR32. The company is not identified as an emerging growth company in its recent 8-K filings, reflecting its status as a large, established issuer.
FAQs about Cencora, Inc. (COR)
Similar Stocks
See how related companies performed
Frequently Asked Questions
Cencora Inc. investment returns
How much would $1,000 invested in Cencora Inc. be worth today?
If you invested $1,000 in Cencora Inc. (COR) 10 years ago on 2016-07-11, your investment would be worth $3,680 today, representing a +268.0% total return, growing at a compounded rate of 13.9% per year (CAGR).
Has Cencora Inc. outperformed the S&P 500?
Over the past 10 years, COR returned +268.0% compared to +249.3% for the S&P 500, outperforming the benchmark by 18.7 percentage points.
What is Cencora Inc.'s average annual return?
The compound annual growth rate (CAGR) of COR over the past 10 years is 13.9%, growing at a compounded rate each year. Individual years vary significantly — COR's best recent year was 2025 (+50.3%) and worst was 2018 (-20.9%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
